ERBB2 and breast carcinoma: Trastuzumab is the first anti-HER2 monoclonal antibody which is effective in the treatment of breast cancer overexpressing HER2 and is a standard option together with chemotherapy in the treatment of HER2-positive metastatic gastric cancer (4–6).